BridgeBio study links Attruby to lower risk of clinical worsening than tafamidis
BridgeBio's ATTR-CM drug acoramidis, sold as Attruby, was associated with a 34% lower risk of clinical worsening than Pfizer's tafamidis in a US real-world study, the company said in September.
Get analysis like this in your inbox.
Join investors and analysts following Lex Commentary.
BridgeBio's ATTR-CM drug acoramidis, sold as Attruby, was associated with a 34% lower risk of clinical worsening than Pfizer's tafamidis in a US real-world study, the company said in September.
The retrospective analysis used insurance claims linked with specialty pharmacy data. After weighting, it compared 170 acoramidis patients with 448 tafamidis patients over a mean follow-up of about 4.6 months. Clinical worsening was defined as escalation of diuretic therapy, heart failure hospitalization or death. The hazard ratio was 0.66.
Separately, BridgeBio has cited an independent propensity-matched analysis of 286 patient pairs that linked acoramidis to a 37% reduction in composite cardiovascular events at six months.
The studies are observational and cannot establish superiority. The company noted the short follow-up and the limits of claims data, including limited capture of disease-severity measures. The FDA has published guidance on how such data can be assessed.
No randomized head-to-head trial of the two drugs has been conducted. Pfizer's tafamidis has been on the market since 2019.